Affymax, Inc. (Nasdaq: AFFY) today announced that it will webcast an analyst briefing on Tuesday, January 10 at 7:15 a.m. PT. During the event, Affymax management will provide a general business update including a discussion of the peginesatide development program.

The live webcast, to begin at 7:15 a.m. PT, may be accessed from the investors section of the company's website at www.affymax.com. A replay will also be available for 30 days following the presentation.

About Peginesatide

Peginesatide is a synthetic PEGylated peptidic compound that binds to and stimulates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent (ESA). The peginesatide Phase 3 clinical program was the largest to support the new drug application of an ESA in the treatment of anemia in chronic kidney disease (CKD) and the first to prospectively evaluate the cardiovascular safety of an ESA via an analysis of independently adjudicated cardiovascular events. The compound was discovered by Affymax and is being co-developed by Affymax and Takeda. If approved, peginesatide may be the first once-monthly product for anemia in CKD for dialysis patients available in the United States.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. For additional information, please visit www.affymax.com.

This release contains forward-looking statements, including statements regarding the timing and potential for the Food and Drug Administration (FDA) approval of peginesatide following the Oncologic Drug Advisory Committee (ODAC) recommendation, continuation and success of Affymax's collaboration with Takeda, timing, design and progress of the peginesatide development program. Affymax's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to the approvability of the New Drug Application (NDA) filing, risks relating to regulatory requirements and approvals, including pre-or post-marketing studies and Risk Evaluation and Mitigation Strategy (REMS), in particular the FDA's interpretation of the ODAC recommendations and its interpretation and review of the data in the NDA including issues related to the subgroup analyses in non-dialysis, study design, the completeness of the NDA, including data quality and integrity in our non-inferiority designed trials, the continued safety and efficacy of peginesatide in clinical development, the timing of patient accrual in ongoing and planned clinical studies, research and development efforts, industry and competitive environment, potential delays or additional studies that may be required by the FDA or other regulatory authorities, financing requirements and our ability to access capital and other matters that are described in Affymax's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Affymax undertakes no obligation to update any forward-looking statement in this press release.

Affymax, Inc.
Sylvia Wheeler, 650-812-8861
Vice President, Corporate Communications